Inventurus Knowledge Solutions
Book Building issueMainboardNSE₹2,498 Cr issue
+39.65%
Listing gain over issue price
Issue size
₹2,498 Cr
1 lot at cut-off
₹14,619
Lot size
11shares
Open
12 Dec 2024
Close
16 Dec 2024
Allotment
17 Dec 2024
Listing
19 Dec 2024
Listing performance
Issue price
₹1,329
Listed at
₹1,856
Listing-day close
₹1,960.85
Latest price
₹1,618
Close on 23 Oct 2026
Listing gain
+39.65%
Return since issue
+21.75%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 12 Dec 2024 – 16 Dec 2024
- Listing date
- 19 Dec 2024
- Face value
- ₹1 per share
- Issue price
- ₹1,329 per share
- Lot size
- 11 shares
- Issue type
- Book Building issue
- Listing at
- NSE
- Total issue size
- ₹2,498 Cr
- Market cap at offer price
- ₹22,802 Cr
- Promoter holding
- 67.66% → 63.72% pre-issue → post-issue
- ISIN
- INE115Q01022
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- ICICI Securities Ltd.
- Registered office
- Building No.5 & 6, Unit No.801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airoli, Navi Mumbai, Maharashtra
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 84,28,730 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 11 shares per lot, in multiples, at ₹1,329
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 11 | ₹14,619 |
| Retail (max) | 13 | 143 | ₹1,90,047 |
| S-HNI (min) | 14 | 154 | ₹2,04,666 |
| S-HNI (max) | 68 | 748 | ₹9,94,092 |
| B-HNI (min) | 69 | 759 | ₹10,08,711 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
84,28,730
Anchor portion
₹1,120 Cr
at ₹1,329 per share
Valuation and performance
Valuation at offer price
₹1,329 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 21.59 | 24.31 |
| P/E (×) | 61.56 | 54.67 |
| Price to book (×) | 19.07 | — |
| Market cap | — | ₹22,802 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 32.00%
- ROCE
- 31.56%
- Debt / equity
- −0.06
- PAT margin
- 20.38%
- NAV per share
- ₹69.70
- Price to book
- 19.07
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Inventurus Knowledge Solutions
Inventurus Knowledge Solutions Limited (IKS) is a publicly listed healthcare technology company incorporated in 2006 and converted to a public limited company in 2022. The company provides a comprehensive care enablement platform assisting healthcare enterprises across outpatient and inpatient care settings. IKS generates revenue from selling technology-enabled healthcare solutions and services to physician enterprises, healthcare organizations, and related entities. The company operates on a globalized, cost-optimized service model with technology infrastructure and employs a significant workforce across India, the US, Australia, and Canada. As of September 30, 2024, IKS served 778 US-based healthcare organizations. The company recently acquired Aquity Holdings, Inc. (October 2023) to expand its capabilities and market presence. IKS operates through multiple subsidiaries including IKS Inc., Aquity Holdings and its group companies, and charitable foundation IKS Cares Foundation.
Company Analysis
from RHPInventurus Knowledge Solutions Limited is a technology-enabled healthcare solutions provider offering revenue optimization and clinical support solutions to US, Canadian, and Australian physician enterprises, operating primarily through software platforms and globalized service delivery.
Inventurus Knowledge Solutions Limited (IKS) is a publicly listed healthcare technology company incorporated in 2006 and converted to a public limited company in 2022. The company provides a comprehensive care enablement platform assisting healthcare enterprises across outpatient and inpatient care settings. IKS generates revenue from selling technology-enabled healthcare solutions and services to physician enterprises, healthcare organizations, and related entities. The company operates on a globalized, cost-optimized service model with technology infrastructure and employs a significant workforce across India, the US, Australia, and Canada. As of September 30, 2024, IKS served 778 US-based healthcare organizations. The company recently acquired Aquity Holdings, Inc. (October 2023) to expand its capabilities and market presence. IKS operates through multiple subsidiaries including IKS Inc., Aquity Holdings and its group companies, and charitable foundation IKS Cares Foundation.
Healthcare ITHealthcare ServicesMedical coding and billing servicesRevenue cycle managementClinical data analyticsHealthcare consulting services
Objects of the Issue
- The objects of the Offer are to (i) carry out the Offer for Sale of up to 18,795,510 Equity Shares of face value of ₹ 1 each by the Selling Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges. Further, our Company expects that listing of the Equity Shares will enhance our visibility and brand image and provide liquidity to our Shareholders and will also provide a public market for the Equity Shares in India. p.25
- General corporate purposes and working capital p.53
- Offer for Sale p.102
- Offer for Sale p.159
Issue Structure
- Total Issue
- Up to 18,795,510 Equity Shares of face value of ₹ 1 each aggregating up to ₹ [●] million
- Offer for Sale
- Up to 18,795,510 Equity Shares of face value of ₹ 1 each aggregating up to ₹ [●] million (100% Offer for Sale)
- Price Band
- [●] (Floor Price and Cap Price to be determined)
- Lot Size
- [●] Equity Shares (minimum bid lot size to be advertised)
- Face Value
- ₹ 1 per Equity Share
Business Model
IKS earns revenue from the sale of its technology-enabled healthcare solutions and services to healthcare organizations. These include Revenue Optimization Solutions (encompassing patient scheduling, clinical coding, billing, payment posting, denial management, and accounts receivable follow-up across multiple care stages), Clinical Support Solutions (including clinical documentation, coding, and risk adjustment tools), and Unifying Data Platform solutions that aggregate and normalize healthcare data. The company operates on a globalized delivery model with cost optimization and on-demand scalability, serving primarily US-based clients with operations in India, US, Australia, and Canada.
Business Segments
Enable healthcare organizations to generate, capture and optimize their revenue, improve operational efficiencies, and increase enterprise value through a cost-optimized, globalized, technology-enabled offering with on-demand scalability. Offerings include patient scheduling services (Pre-Visit Stage), clinical coding solutions and referral order management (Peri-Visit Stage), Billing, Payment Posting, Denial Management, Account Receivables Follow Up, and IKS Optimix (Post Visit Stage), and solutions for In-Acute Settings Stage.
Provided at each stage and include IKS Scribble, IKS Stacks, IKS AssuRx and IKS Migrate. Also provide clinical chart review and Hierarchical Condition Codes (HCC) coding solutions which cater to the Value Based Care (VBC) portfolio.
Enables healthcare organizations to ingest, aggregate, normalize, sort and clean clinical, financial and administrative data for a provider enterprise into a single enterprise data warehouse.
Technology-enabled clinical documentation and medical coding solutions
Revenue optimization and denial prevention solutions
Autonomous Administrative Platform and clinical support services
Financial process in healthcare that involves managing claims, payments, and revenue generation, ensuring the efficient flow of funds from patient to provider
Essential tools for clinical decision-making and care coordination encompassing diagnostic support, treatment planning, and seamless communication among healthcare professionals
Solutions that focus on patient outcomes, quality, and cost-effectiveness in healthcare, gaining traction among healthcare providers
Enable physicians to focus more on patient care by reducing their time and effort spent on documentation
Involves methodical processes to accurately code medical procedures and diagnoses, optimizing billing, compliance, and data management
Enables healthcare organizations to generate, capture and optimize their revenue through patient scheduling, insurance verification, eligibility verification, prior authorization, coding, billing, payment posting, denial management, and account receivables follow-up across pre-visit, peri-visit, post-visit, and in-acute settings.
Provides clinical documentation through virtual scribing (Scribble), pre-visit summaries, clinical data abstraction (Stacks), prescription refill automation (AssuRx), clinical data migration (Migrate), and discharge summary creation to reduce administrative burden on physicians and clinical staff.
Offers clinical chart review, hierarchical condition codes (HCC) coding, and data platform solutions to help healthcare organizations accurately capture patient risk, identify disease conditions proactively, and improve population health outcomes.
Assists U.S. based healthcare service providers deliver better, safer, and more efficient care using a combination of outsourcing and technology
Assists U.S. based healthcare service providers deliver better, safer, and more efficient care using a combination of outsourcing and technology through medical transcription, medical coding, virtual medical scribing solutions, and related services and technology
Clinical documentation solutions provider engaged in the provision of Medical Transcription services and Information Technology enabled Services in the nature of Quality Assurance, Back Office support services, Information Technology support services, record management, medical coding services and scribing services
Provider of medical transcription, medical coding, virtual medical scribing solutions, and related services and technology
Providing of medical transcription, medical coding, virtual medical scribing solutions, and related services and technology
Engaged in the business of furthering and advancing any public charitable purpose, authorized under the objects clause of its Memorandum of Association
The Group operates in one reportable business segment providing focused cost and process optimization solutions to clients in the healthcare industry, including revenue cycle management, medical coding, transcription, and clinical documentation services
Delivers medical transcription, coding, and scribe services; assists healthcare providers manage insurance collections and clinical workflow
Technology-enabled clinical documentation, medical coding, revenue integrity solutions and scribe services for healthcare providers across the healthcare value chain including front, middle and back offices
SWOT Analysis
Strengths
- • Technology-enabled healthcare solutions platform with comprehensive care enablement offerings(p.24)
- • Diversified revenue optimization solutions across patient journey stages(p.24)
- • Significant customer base with 778 US-based healthcare organizations(p.24)
- • Strong financial performance with revenue growth and profitability(p.27)
- • Established internal audit and compliance processes with third-party oversight(p.86)
- • Anti-corruption compliance framework in place with no violations in recent periods(p.86)
- • Comprehensive one-stop platform with diversified offerings across outpatient and inpatient care value chain(p.162)
- • Strong brand with clinical thought leadership and multiple awards/recognitions(p.162)
- • Marquee large enterprise clientele with high repeat client revenue (>98%) over three fiscals(p.162)
- • Sustainable and scalable business model with high-touch client engagement(p.162)
- • Healthy financial performance with growth and improving margins(p.162)
- • Experienced and entrepreneurial-driven leadership team(p.162)
- • Strategic acquisition of Aquity Holdings in October 2023 enhanced inpatient and outpatient capabilities(p.199)
- • Global delivery advantage with 24/7 service model addressing U.S. healthcare workforce shortages(p.200)
- • Comprehensive integrated platform across full healthcare value chain(p.213)
- • Significant revenue and EBITDA growth with strong margins(p.211)
- • Large clinically-trained workforce with specialized expertise(p.214)
- • Strong proprietary technology platform with AI/ML capabilities(p.231)
- • Annuity-based revenue model providing stability(p.220)
- • Successful long-term client relationships with strong cross-sell potential(p.219)
- • Strategic collaboration with industry leaders for product innovation(p.217)
- • Tech-enabled healthcare provider platform with diversified solutions across value chain(p.305)
- • EBITDA positive since 2014 with strong financial growth trajectory(p.252)
- • Crossed $100 million revenue milestone by 2022(p.252)
- • Registered 'IKS Health' brand with US Patent and Trademark Office(p.252)
- • Established healthcare IT service delivery model with diversified customer base(p.311)
- • Significant goodwill and intangible assets from strategic acquisition(p.319)
- • Strong financial position with substantial cash and liquid resources(p.322)
- • Significant intangible asset base including customer relationships(p.319)
- • Established revenue base with consistent growth trajectory(p.489)
- • Diversified service offerings across healthcare domain(p.489)
- • Strategic market expansion through Aquity acquisition(p.489)
- • Profitable operations with positive EBITDA margins(p.491)
Weaknesses
- • FEMA compliance deficiencies and pending compounding applications with RBI(p.31)
- • Estimated penalty exposure of ₹2.70-3.00 million for FEMA contraventions(p.41)
- • Outstanding litigation against the company(p.28)
- • Dependence on few key clients(p.28)
- • Limited integration experience with recent Aquity Holdings acquisition(p.28)
- • Promoter litigation and SEBI enforcement action(p.46)
- • Shareholder disputes and oppression allegations(p.45)
- • High attrition rates affecting workforce stability(p.66)
- • Significant borrowings post-acquisition(p.59)
- • DRI penalties for misclassification of export services(p.45)
- • Subsidiary penalties for export benefit misclassification(p.45)
- • Loss of major customer representing 4% of revenue(p.51)
- • One Promoter lacks educational documentation(p.68)
- • Internal control deviations and limitations in ensuring effective checks and balances(p.86)
- • Risk of financial reporting errors due to human error and lapses in judgment(p.86)
- • Promoter concentration and continued majority shareholder control post-IPO(p.87)
- • Measurement challenges and potential inaccuracies in operational metrics tracking(p.87)
- • Inability to assure future dividend payments(p.87)
- • Significant portion of operations concentrated in US geographic area(p.88)
- • Partly-paid equity shares issued without RBI approval and pending regulatory resolution(p.119)
- • Delayed regulatory filings on ESOP and FC-TRS forms with compounding applications pending(p.119)
- • Current market penetration less than 1% despite large addressable market(p.198)
- • Significant geographic concentration of workforce (77.2% in India) creates operational and talent retention risks(p.199)
- • Heavy concentration of revenue in top clients(p.219)
- • Significant margin compression post-Aquity acquisition(p.211)
- • High employee benefit costs as percentage of revenue(p.240)
- • Significant decline in free cash flow(p.212)
- • Highly dependent on acquisition integration success(p.206)
- • Significant loss at Indian subsidiary (Aquity India) post-acquisition with 58.42% negative margin(p.259)
- • Dependence on key personnel including founder-promoter Sachin Gupta(p.265)
- • Promoter educational records incomplete - Rekha Jhunjhunwala records not traceable(p.281)
- • RBI approval still pending for equity share capital transactions(p.294)
- • Substantial debt burden from acquisition financing(p.326)
- • High employee benefit obligations and liabilities(p.327)
- • Lease obligations creating fixed cost burden(p.317)
- • Contingent liabilities and pending litigation exposures(p.336)
- • Concentration of shareholder holdings among promoters(p.324)
- • Significant contingent liabilities from employee provident fund disputes in India(p.402)
- • Customer concentration risk with single customer representing 5% of revenue and 13% of receivables(p.411)
- • Material pending arbitration case from former Chief Commercial Officer(p.403)
- • High leverage with significant borrowings relative to equity(p.409)
- • High dependence on limited client base for revenue(p.500)
- • Significant increase in finance costs post-acquisition(p.490)
- • Deteriorating profit margins due to Aquity integration and higher debt burden(p.491)
- • Pending FEMA compliance matters and regulatory uncertainties(p.31)
- • Multiple pending litigation matters related to subsidiary's EPFO and customs issues(p.506)
Opportunities
- • Growing outsourced services market in healthcare provider space(p.25)
- • Strategic expansion through recent Aquity acquisition(p.28)
- • Potential development of AI and machine learning-powered solutions(p.28)
- • Enhanced market visibility and brand image through public listing(p.25)
- • Expansion of AI/ML capabilities in healthcare solutions(p.46)
- • Large upfront payment contract with 15-year term(p.50)
- • Growth in number of high-value clients(p.74)
- • Expansion beyond US into Canada and Australia(p.63)
- • Strategic investment in AI-enabled medical records technology(p.52)
- • Growth through inorganic acquisitions and strategic investments(p.119)
- • Total Addressable Market of USD 222 billion in provider-centric technology solutions with significant growth potential(p.198)
- • Outsourced healthcare provider services market growing at 11.7% CAGR with USD 34 billion TAM(p.198)
- • Revenue Cycle Management segment growing at 13% CAGR with USD 18 billion TAM and only 18% market penetration(p.197)
- • Value-Based Care segment growing at 21% CAGR, representing highest growth opportunity(p.196)
- • Clinical Services outsourcing growing at 10% CAGR with USD 7.7 billion TAM and only 11% market penetration(p.197)
- • U.S. healthcare spending projected to grow at 5.3% CAGR from USD 4.8 trillion in 2023 to USD 6.2 trillion by 2028(p.177)
- • Growing shift towards Value-Based Care model with nearly 25% of health payments tied to alternative payment models(p.186)
- • Rapidly expanding US healthcare provider enablement market(p.209)
- • Significant untapped market penetration opportunity(p.211)
- • Growing adoption of value-based care models(p.211)
- • Shift toward technology-led automation reducing manual processes(p.223)
- • Leverage generative AI and advanced automation capabilities(p.224)
- • Expansion into inpatient care through Aquity acquisition(p.209)
- • Growing healthcare provider consolidation driving demand(p.222)
- • Substantial cross-sell opportunity within existing client base(p.224)
- • Expansion of healthcare solutions platform across US-based healthcare providers(p.305)
- • Potential to build on recent Aquity Holdings acquisition valued at $221.4 million(p.253)
- • Leverage technology-led provider-enabled platforms for growth(p.251)
- • Expansion through acquired Aquity's healthcare IT service capabilities(p.319)
- • Growth in healthcare IT services market segment(p.331)
- • International expansion through multi-geography subsidiary presence(p.334)
- • Software license and product revenue diversification(p.331)
- • Expansion of software licensing revenue streams(p.487)
- • Growth through wallet share expansion and cross-sell to existing clients(p.489)
- • Market consolidation through M&A with complementary businesses(p.489)
- • Increased use of technology and enhanced digital solutions(p.490)
Threats
- • Geographic and sector concentration risk from US healthcare dependency(p.28)
- • Regulatory and compliance risks in US healthcare industry(p.28)
- • US healthcare industry challenges and consolidation(p.28)
- • Foreign currency exchange rate fluctuation exposure(p.28)
- • International operations complexity in US, Australia and Canada(p.22)
- • Risk of technology implementation failure(p.22)
- • Extreme healthcare industry consolidation reducing client base(p.48)
- • Regulatory restrictions on offshore delivery of clinical services(p.47)
- • EHR vendor policy restrictions on non-US vendors(p.69)
- • Healthcare legislative and pricing pressure reform(p.75)
- • Intense competition from established and emerging players(p.70)
- • Dependence on US market with 99.94% of revenues(p.54)
- • HIPAA and state privacy law compliance requirements(p.60)
- • Foreign currency exchange rate volatility(p.61)
- • FEMA compliance violations and RBI regulatory action risk(p.46)
- • Potential loss of SEZ tax benefits(p.58)
- • Adverse global economic conditions affecting Indian and US markets(p.88)
- • US policy changes and economic slowdown impacting healthcare client spending(p.88)
- • Indian political and economic instability affecting business operations(p.88)
- • Impact of India's sovereign debt downgrade on borrowing costs and market access(p.89)
- • Changes in tax laws reducing benefits and increasing compliance burden(p.89)
- • Increased labour costs from new labour codes and social security requirements(p.89)
- • Inflation reducing margins if unable to pass on cost increases to clients(p.91)
- • Financial instability in other countries causing volatility in Indian markets(p.90)
- • Exchange rate fluctuations reducing foreign investor returns(p.94)
- • Intense competition from non-traditional healthcare disruptors including retail clinics and tech companies like Amazon(p.187)
- • Rising healthcare labor costs and physician burnout threatening operational margins(p.179)
- • Stringent healthcare regulations and compliance requirements limiting technology innovation(p.193)
- • Cybersecurity and data privacy risks with increased digitization of healthcare systems(p.194)
- • Projected U.S. physician shortage of 124,000 by 2034 reducing addressable customer base(p.191)
- • Changing healthcare reimbursement models creating revenue uncertainty for providers and service vendors(p.192)
- • Rapid technological disruption and AI advancement competition(p.203)
- • Data security and privacy regulatory compliance risks(p.204)
- • Complex EHR interoperability and integration challenges(p.204)
- • Intense competition from specialized and large-scale vendors(p.204)
- • User adoption and behavioral resistance to new digital workflows(p.204)
- • Talent acquisition and retention in specialized healthcare IT fields(p.204)
- • Complex and evolving healthcare regulatory landscape(p.204)
- • AI/ML algorithm accuracy and bias risks(p.204)
- • Regulatory compliance requirements from US health authorities (HIPAA, HITECH Act)(p.249)
- • TCPA restrictions limiting use of automated calling systems and pre-recorded messages(p.249)
- • FCPA compliance requirements for international operations and foreign official interactions(p.250)
- • OFAC sanctions and restrictions on transactions with sanctioned entities(p.250)
- • Significant amortization burden from intangible assets acquired(p.333)
- • Foreign exchange exposure from USD-denominated operations(p.322)
- • Provision for contingent SEIS liabilities from acquisition(p.327)
- • Material outstanding contingent consideration obligations(p.326)
- • High finance costs from debt servicing(p.331)
- • Ongoing investigation and potential liability related to SEIS duty credit scrips in India(p.403)
- • Regulatory risk related to tax compliance in multiple jurisdictions(p.403)
- • Entire business operations concentrated in United States healthcare sector(p.411)
- • Loss of major clients could materially impact revenues(p.51)
- • Foreign currency exchange rate volatility impacts results(p.56)
- • Seasonal fluctuations in revenue from operations(p.77)
- • Ongoing regulatory investigations related to export benefits and customs matters(p.509)
- • Competitive pressure and market conditions affecting margins(p.500)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Sachin Gupta | Individual Promoter | 10.23% | — |
| Rekha Jhunjhunwala | Individual Promoter | 0.23% | — |
| Aryaman Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Aryavir Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Nishtha Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Rekha Jhunjhunwala | Promoter | — | — |
| Utpal Hemendra Sheth | Promoter | — | — |
| Rajeshkumar Radheshyam Jhunjhunwala | Promoter | — | — |
| Sachin Gupta | Promoter | 10.23% | [●] |
| Aryaman Jhunjhunwala Discretionary Trust | Promoter | 17.37% | [●] |
| Aryavir Jhunjhunwala Discretionary Trust | Promoter | 17.37% | [●] |
| Nishtha Jhunjhunwala Discretionary Trust | Promoter | 17.44% | [●] |
| Rekha Jhunjhunwala | Promoter | 0.23% | [●] |
| Sachin Gupta | Promoter | 10.23% | — |
| Aryaman Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Aryavir Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Nishtha Jhunjhunwala Discretionary Trust | Promoter | 17.37% | — |
| Rekha Jhunjhunwala | Promoter | 0.23% | — |
| Sachin Gupta | Promoter | 10.23% | — |
| Rekha Jhunjhunwala | Promoter | 0.23% | — |
| Aryaman Jhunjhunwala Discretionary Trust | Promoter Group | — | — |
| Aryavir Jhunjhunwala Discretionary Trust | Promoter Group | — | — |
| Nishtha Jhunjhunwala Discretionary Trust | Promoter Group | — | — |
| Inventurus Knowledge Solutions Limited | Ultimate Holding Entity | — | 100% |
| Rekha Jhunjhunwala | Promoter | — | — |
| Sachin Gupta | Promoter | — | — |
| Aryaman Jhunjhunwala Discretionary Trust | Promoter | — | — |
| Aryavir Jhunjhunwala Discretionary Trust | Promoter | — | — |
| Nishtha Jhunjhunwala Discretionary Trust | Promoter | — | — |
| Rekha Jhunjhunwala | Promoter Group | — | — |
| Sachin Gupta | Promoter/Promoter Group Selling Shareholder | — | — |
Leadership
Sachin Gupta · Executive Director / Whole-time Director and Individual Promoter
Berjis Minoo Desai · Chairman
Nithya Balasubramanian · Chief Financial Officer
Sameer Chavan · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Inventurus Knowledge Solutions IPO FAQs
What is the lot size of Inventurus Knowledge Solutions IPO?
The minimum lot size of Inventurus Knowledge Solutions IPO is 11 shares. One lot costs ₹14,619 at the cut-off price.
When does Inventurus Knowledge Solutions IPO open and close?
Inventurus Knowledge Solutions IPO opened for subscription on 12 Dec 2024 and closed on 16 Dec 2024.
What is the listing date of Inventurus Knowledge Solutions IPO?
Inventurus Knowledge Solutions IPO listed on 19 Dec 2024.